Calidi Biotherapeutics proposed a 1-for-16 reverse stock split of its outstanding common stock, effective July 31, 2026. The move can signal underlying capital/price-support concerns and is likely to weigh on sentiment, though it is not necessarily indicative of an operating turnaround in itself.
Calidi Biotherapeutics proposed a 1-for-16 reverse stock split of its outstanding common stock, effective July 31, 2026. The move can signal underlying capital/price-support concerns and is likely to weigh on sentiment, though it is not necessarily indicative of an operating turnaround in itself.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
